Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown. METHODS: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors). RESULTS: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. CONCLUSIONS: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [136]
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Research works printed but not linked: 2
- 10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · DOI · Paper page
- 10.1002/(sici)1097-0215(19990621)84:3<326::aid-ijc22>3.0.co;2-k · DOI · Paper page
Cited by
Items 601–700 of 1,001
Gnjatic, S., Cao, Y., Reichelt, U., Yekebas, E. F., Nölker, C., Marx, A. H., Erbersdobler, A., Nishikawa, H., Hildebrandt, Y., Bartels, K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.25058 · Cited by 67
“It has been suggested that T cell infiltration may contribute to improve the patients’ prognosis by eradicating micrometastases,(3) and, accordingly, T cell responses within colorectal carcinoma are associated with the absence of signs of early metastatic invasion such as vascular emboli and lymphatic or perineural in…”
BackgroundResultNanotechnologies for the treatment of colon cancer: From old drugs to new hope
Kotelevets, L., Chastre, E., Desmaële, D., & Couvreur, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.005 · Cited by 66
Ecker, C., Guo, L., Voicu, S., Gil‐de‐Gómez, L., Medvec, A. R., Cortina, L. E., Pajda, J., Andolina, M., Torres-Castillo, M., Donato, J. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.084 · Cited by 67
“Human T EM cells are the most common T cell to reside in the tumor microenvironment and other inflamed environments (Farber et al., 2014; Pagès et al., 2005; Thome et al., 2014).”
Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer
Waidhauser, J., Schuh, A., Trepel, M., Schmälter, A., & Rank, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02449-y · Cited by 65
Liu, F., Hu, X., Zimmerman, M. A., Waller, J. L., Wu, P., Hayes-Jordan, A. A., Lev, D. C., & Liu, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016241 · Cited by 66
“human colorectal tumors [5,6,7,8].”
Evaluating biomarkers in melanoma
Karagiannis, P., Fittall, M. W., & Karagiannis, S. N. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00383 · Cited by 74
“The potential value of immune sentinels in cancer could be exemplified by reports that monitoring tumor infiltrating lymphocytes (TIL) (immune score) may be more accurate prognostically than standard methods such as TNM stage (110, 111).”
MethodGranulysin-Mediated Tumor Rejection in Transgenic Mice
Huang, L. P., Lyu, S., Clayberger, C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.77 · Cited by 61
“More recently, colorectal cancer patients have prolonged survival associated with increased level of GNLY mRNA in effector T cells in tumors without early invasion (31).”
BackgroundResultInfluentialHu, J., Kinn, J., Zirakzadeh, A. A., Sherif, A., Norstedt, G., Wikström, A.-C., & Winqvist, O. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12060 · Cited by 61
Muthuswamy, R., Wang, L., Pitteroff, J., Gingrich, J. R., & Kaliński, P. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0050-8 · Cited by 63
“Tumor infiltration with effector CD8 T cells (CTL) has been associated with good prognosis in various cancers [5-18], therefore immunotherapies able of enhancing intra-tumoral CTL levels may be also effective for invasive bladder cancers.”
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer
Drescher, K. M., Sharma, P., Watson, P. A., Gatalica, Z., Thibodeau, S. N., & Lynch, H. T. (2009) · Familial Cancer · doi:10.1007/s10689-009-9233-0 · Cited by 66
“[57] demonstrated that CRC patients with”
Colitis-associated neoplasia: molecular basis and clinical translation
Foersch, S., & Neurath, M. F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1636-x · Cited by 69
Telomerase as a universal tumor antigen for cancer vaccines
Beatty, G. L., & Vonderheide, R. H. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.881 · Cited by 72
Bini, E. J., Park, J. S., & François, F. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1626 · Cited by 72
Väyrynen, J. P., Kantola, T., Väyrynen, S. A., Klintrup, K., Bloigu, R., Karhu, T., Mäkelä, J. T., Herzig, K., Karttunen, T. J., Tuomisto, A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30040 · Cited by 65
Espinoza, J. A., Jabeen, S., Batra, R., Papaleo, E., Haakensen, V. D., Wielenga, V. T., Talman, M., Brünner, N., Børresen‐Dale, A., Gromov, P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248015 · Cited by 73
Jia, B., Zhao, C., Rakszawski, K. L., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Wang, M., Shike, H., Bayerl, M. G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3107 · Cited by 70
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 66
Lönnroth, C., Andersson, M., Arvidsson, A., Nordgren, S., Brevinge, H., Lagerstedt, K., & Lundholm, K. (2008) · PubMed · Cited by 66
Baker, K., Zlobec, I., Tornillo, L., Terracciano, L., Jass, J. R., & Lugli, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.012 · Cited by 64
Durazzo, T. S., Tigelaar, R. E., Filler, R. B., Hayday, A., Girardi, M., & Edelson, R. L. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.11.008 · Cited by 60
“immunocompetent cutaneous T cell lymphoma (CTCL) patients, including some complete and long term remissions[2-4].”
BackgroundVariation of Tumor-Infiltrating Lymphocytes in Human Cancers: Controversy on Clinical Significance
Sasada, T., & Suekane, S. (2011) · Immunotherapy · doi:10.2217/imt.11.106 · Cited by 61
Umansky, V., Abschütz, O., Osen, W., Ramacher, M., Zhao, F., Kato, M., & Schadendorf, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1464 · Cited by 69
“It is worthwhile to note that in patients with colorectal cancer, significant tumor infiltration with EM CD8 T lymphocytes has been reported to correlate with an absence of early metastatic invasion, a less advanced pathologic stage, and increased survival (35).”
BackgroundResultPaulsen, E., Kilvaer, T. K., Rakaee, M., Maurseth, R. J., Al‐Saad, S., Hald, S. M., Al-Shibli, K. I., Andersen, S., Richardsen, E. H., Busund, L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.11.004 · Cited by 64
Tomé, M., Pappalardo, A., Soulet, F., López, J. J., Olaizola, J., Léger, Y., Dubreuil, M., Mouchard, A., Fessart, D., Delom, F., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0086 · Cited by 60
Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
Fassler, D., Torre-Healy, L. A., Gupta, R., Hamilton, A. M., Kobayashi, S., Alsten, S. C. V., Zhang, Y., Kurç, T., Moffitt, R. A., Troester, M. A., et al. (2022) · Cancers · doi:10.3390/cancers14092148 · Cited by 64
Oguro, S., Ino, Y., Shimada, K., Hatanaka, Y., Matsuno, Y., Esaki, M., Nara, S., Kishi, Y., Kosuge, T., & Hiraoka, N. (2015) · Cancer Science · doi:10.1111/cas.12825 · Cited by 68
Brudvik, K. W., Henjum, K., Aandahl, E. M., Bjørnbeth, B. A., & Taskén, K. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1174-4 · Cited by 59
Sahiratmadja, E., Alisjahbana, B., Buccheri, S., et al. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.01.002 · Cited by 59
“Median age [range] (years) 29 [17–56]”
Nakasone, Y., Fujimoto, M., Matsushita, T., Hamaguchi, Y., Huu, D. L., Yanaba, M., Sato, S., Takehara, K., & Hasegawa, M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.005 · Cited by 63
Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
Assal, A., Kaner, J. D., Pendurti, G., & Zang, X. (2015) · Immunotherapy · doi:10.2217/imt.15.78 · Cited by 59
Vacchelli, E., Enot, D. P., Pietrocola, F., Zitvogel, L., & Kroemer, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0294 · Cited by 59
“For over a decade, there has been no doubt that the density, distribution, composition, and functional state of the anticancer immune infiltrate, as found at the stage of diagnosis, has a major impact on the natural course of malignant diseases (2, 3), as well as on treatment responses to chemotherapeutic agents or so…”
BackgroundLee-Chang, C., Bodogai, M., Moritoh, K., Olkhanud, P. B., Chan, A. C., Croft, M., Mattison, J. A., Holst, P. J., Gress, R. E., Ferrucci, L., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563940 · Cited by 58
“05, Figure 4D and supplemental Figure 5B), a key antitumor requirement.(39) The GrB(1)CD8(1) T cells also were strongly expanded ex vivo if pulsed with gp10025-32 peptide (supplemental Figure 5C), confirming the tumor (gp100) specificity.”
BackgroundTransient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy
Gutwillig, A., Santana-Magal, N., Farhat-Younis, L., Rasoulouniriana, D., Madi, A., Luxenburg, C., Cohen, J., Padmanabhan, K., Shomron, N., Shapira, G., et al. (2022) · eLife · doi:10.7554/elife.80315 · Cited by 62
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
Coppola, A., Arriga, R., Lauro, D., et al. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00033 · Cited by 58
“Infiltration of the CRC tumor microenvironment by tumor-associated macrophages (12–14), CD8 T-cells (15), and CD4 regulatory T-cells (16) is an independent favorable prognostic factor for CRC.”
BackgroundZlobec, I., Karamitopoulou, E., Terracciano, L., Piscuoglio, S., Iezzi, G., Muraro, M. G., Spagnoli, G., Baker, K., Tzankov, A., & Lugli, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014282 · Cited by 57
“Although the prognostic significance of abundant CD8+ TILs has previously been established [3,5,15,16,17], this study goes one step further to identify the marker TIA-1 as a highly relevant prognostic parameter in colorectal cancer and particularly in tumors with marked cytotoxic CD8+ TILs.”
BackgroundRyan, A. E., Colleran, A., O'Gorman, A., O’Flynn, L., Pindjacova, J., Lohan, P., O’Malley, G., Nosov, M., Mureau, C., & Egan, L. J. (2014) · Oncogene · doi:10.1038/onc.2014.86 · Cited by 62
Lymph node ratio predicts disease‐specific survival in melanoma patients
Xing, Y., Badgwell, B. D., Ross, M. I., et al. (2009) · Cancer · doi:10.1002/cncr.24290 · Cited by 58
“5 (11-23) 11 (7-16) Median LN ratio (IQR) 0.”
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma
Kadota, K., Nitadori, J., Ujiie, H., Buitrago, D., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., & Adusumilli, P. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000617 · Cited by 60
Kaewkangsadan, V., Verma, C., Eremin, J. M., Cowley, G., Ilyas, M., & Eremin, O. (2016) · Journal of Immunology Research · doi:10.1155/2016/4757405 · Cited by 66
“A number of studies have shown that the presence of a prominent lymphocytic infiltrate in tumours is associated with an improved prognosis and good long-term clinical outcome in patients with different types of cancer [2, 4–7].”
CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis
Safari, F., Farajnia, S., Aria, M., Zarredar, H., & Nasrolahi, A. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1437625 · Cited by 61
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity
Milutinovic, S., Abe, J., Godkin, A. J., Stein, J. V., & Gallimore, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.001 · Cited by 61
Wankhede, D., Yuan, T., Kloor, M., Halama, N., Brenner, H., & Hoffmeister, M. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00091-8 · Cited by 72
The immune response in cancer: from immunology to pathology to immunotherapy
Giraldo, N. A., Becht, É., Vano, Y. A., Sautès‐Fridman, C., & Fridman, W. H. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1787-7 · Cited by 65
“cell densities and the tumor stage [55] and perineural invasion [56].”
BackgroundSelf-citationVaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
Palena, C., & Schlom, J. (2010) · BioMed Research International · doi:10.1155/2010/380697 · Cited by 62
“In colorectal cancer, for example, significantly higher levels of early memory and effector memory CD8+ T-cell infiltrates positively correlate with good clinical outcome, defined as absence of metastatic invasion, less advanced pathological stage, and increased survival [6, 7].”
BackgroundTumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
Cipponi, A., Wieërs, G., van Baren, N., & Coulie, P. G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1026-2 · Cited by 67
“More recent studies extended these results using highthroughput quantitative measurements of surface markers and of gene expression and showed a correlation between a low incidence of tumor recurrence after surgery and markers of Th1 polarization, cytotoxic, and memory T cells [ 24 , 25].”
ResultMelanoma NOS1 expression promotes dysfunctional IFN signaling
Liu, Q., Tomei, S., Ascierto, M. L., Giorgi, V. D., Bedognetti, D., Dai, C., Uccellini, L., Spivey, T., Pós, Z., Thomas, J. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69611 · Cited by 62
“Although the weight that cellular immune infiltrates bear on the natural history of melanoma has been long known (18, 19), this observation was recently characterized in greater detail and expanded to other cancer types (7, 20, 21).”
T Cells in Gastric Cancer: Friends or Foes
Amedei, A., Bella, C. D., Silvestri, E., Prisco, D., & D’Elios, M. M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/690571 · Cited by 58
“In particular, patients with early-stage cancers but an absence of T-cell infiltrates display poor outcomes, whereas subjects with significant tumor burdens but robust T-cell infiltrates showed improved outcomes [23, 31].”
BackgroundClayberger, C., Finn, M. W., Wang, T., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200570 · Cited by 57
Autoantibodies as Potential Biomarkers in Breast Cancer
Qiu, J., Keyser, B., Lin, Z., & Wu, T. (2018) · Biosensors · doi:10.3390/bios8030067 · Cited by 66
“Also, CD20+ B cells among TIL correlated with favorable prognosis in ovarian cancer [127].”
BackgroundPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
“The process of neoantigen recognition is attenuated by expression of PD-L1 and some other immunosuppressive ligands (Pages et al., 2005; Llosa et al., 2015).”
BackgroundDelivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors
Fu, R., Li, H., Li, R., McGrath, K. V., Dotti, G., & Gu, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009489 · Cited by 58
The biologic importance of tumor‐infiltrating lymphocytes
Hodi, F. S., & Dranoff, G. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01506.x · Cited by 57
A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer
Cornelissen, L. A. M., & van Vliet, S. J. (2016) · Biomolecules · doi:10.3390/biom6020026 · Cited by 62
“In a variety of solid tumors, high frequencies of tumor-infiltrating lymphocytes (TILs) were correlated with increased survival [38–42], whereby high frequencies of memory T cells are particularly associated with a lack of early metastatic invasion [43].”
BackgroundYu, A., Mansure, J. J., Solanki, S., Siemens, D. R., Koti, M., Dias, A. B. T., Burnier, M. M., Brimo, F., & Kassouf, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205746 · Cited by 62
Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
Feist, M., Zhu, Z., Dai, E., Ma, C., Liu, Z., Giehl, E., Ravindranathan, R., Kowalsky, S. J., Obermajer, N., Kammula, U. S., et al. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0189-4 · Cited by 60
Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
Zhang, Q., Chen, G., Liu, X., & Qian, Q. (2007) · Cell Research · doi:10.1038/sj.cr.7310143 · Cited by 65
Marx, A., Kallert, S. M., Brunner, T. M., Villegas, J. A., Geier, F., Fixemer, J., Abreu-Mota, T., Reuther, P., Bonilla, W. V., Fadejeva, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.029 · Cited by 64
Hu, W., Miyai, K. N., Cajas-Monson, L. C., Luo, L., Liu, L., & Ramamoorthy, S. L. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23998 · Cited by 67
Kao, S., Vardy, J. L., Chatfield, M. D., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., & Clarke, S. J. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.03.011 · Cited by 57
Lee, W., Kang, M., Baek, J., Lee, J.-I., & Ha, S. Y. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2752-1 · Cited by 56
Ash, S. A., & Buggy, D. J. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2013.10.005 · Cited by 60
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
Ghiringhelli, F., & Apétoh, L. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865520 · Cited by 60
Atreya, I., Schimanski, C. C., Becker, C., Wirtz, S. J., Dornhoff, H., Schnürer, E., Berger, M. R., Galle, P. R., Herr, W., & Neurath, M. (2007) · Gut · doi:10.1136/gut.2006.117812 · Cited by 65
Hynes, S. O., Coleman, H. G., Kelly, P. J., Irwin, S., O'Neill, R. F., Gray, R. T., McGready, C., Dunne, P. D., McQuaid, S., James, J. A., et al. (2017) · Histopathology · doi:10.1111/his.13181 · Cited by 55
“(36,37) This is despite numerous morphological studies demonstrating prognostic significance of selected tumour microenvironmental features (10-28).”
BackgroundGao, Y. J., Li, S., Xu, D., Chen, S., Cai, Y., Jiang, W., Zhang, X., Sun, J., Wang, K., Chang, B., et al. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0226-3 · Cited by 60
Viganò, L., Soldani, C., Franceschini, B., Cimino, M., Lleò, A., Donadon, M., Roncalli, M. G., Aghemo, A., Tommaso, L. D., & Torzilli, G. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04111-5 · Cited by 58
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Prospects and challenges of building a cancer vaccine targeting telomerase
Vonderheide, R. H. (2007) · Biochimie · doi:10.1016/j.biochi.2007.07.005 · Cited by 62
“across a broad range of histologies [8-12].”
MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment
Mudd, T. W., Lu, C., Klement, J. D., & Liu, K. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104260 · Cited by 64
“Due to this function, CTL infiltration into the tumor of colorectal tumors has been evaluated as a prognostic indicator for patient survival and tumor progression [38, 39].”
BackgroundCranioencephalic functional lymphoid units in glioblastoma
Dobersalske, C., Rauschenbach, L., Hua, Y., Berliner, C., Steinbach, A., Grüneboom, A., Kokkaliaris, K. D., Heiland, D. H., Berger, P., Langer, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03152-x · Cited by 65
Gao, Q., Wang, X., Qiu, S., Zhou, J., Shi, Y., Zhang, B., & Fan, J. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01981.x · Cited by 54
Kanagawa, N., Niwa, M., Hatanaka, Y., Tani, Y., Nakagawa, S., Fujita, T., Yamamoto, A., & Okada, N. (2007) · International Journal of Cancer · doi:10.1002/ijc.22908 · Cited by 59
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
Emens, L. A., Silverstein, S. C., Khleif, S. N., Marincola, F. M., & Galon, J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-70 · Cited by 58
“For example, in colon cancers, the density of CD8 T cells within the tumor predicts patient survival [11-13].”
BackgroundSelf-citationPeng, R.-Q., Wu, X.-J., Ding, Y., Li, C.-Y., Yu, X.-J., Zhang, X., Pan, Z.-Z., Wan, D.-S., Zeng, Y.-X., Zeng, Y.-X., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-496 · Cited by 54
Interstitial laser thermotherapy (ILT) of breast cancer
Haraldsdóttir, K. H., Ivarsson, K. M., Götberg, S., Ingvar, C., Stenram, U., & Tranberg, K. ‐. (2008) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2008.01.008 · Cited by 57
Polónia, A., Pinto, R., Cameselle-Teijeiro, J. F., Schmitt, F. C., & Paredes, J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203990 · Cited by 54
The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers
Liu, G., Liu, R., Yan, J.-P., An, X., Wu, J., Ling, Y., Chen, J.-W., Bei, J., Zuo, X.-Y., Cai, M.-Y., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy004 · Cited by 60
“The current study demonstrates that the numbers of CD3þ, CD4þ, CD8þ lymphocytes in CN; CD3þ, CD4þ lymphocytes in TS; and CD3þ, CD8þ, FoxP3þ lymphocytes in IM of Lynch-associated patients were statistically significantly more than those of sporadic patients, which may explain the improved prognosis in patients with Lyn…”
BackgroundInfluentialCrosby, E. J., Hobeika, A. C., Niedzwiecki, D., Rushing, C. N., Hsu, D. S., Berglund, P., Smith, J., Osada, T., Gwin, W. R., Hartman, Z. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001662 · Cited by 59
“Infiltration of colon cancers by CD8+T cells is associated with improved recurrence free survival, 5 which suggests that attempts to augment the immune response against colon cancer may be beneficial.”
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
Gibellini, L., Biasi, S. D., Porta, C., Tartaro, D. L., Depenni, R., Pellacani, G., Sabbatini, R., & Cossarizza, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00490 · Cited by 56
Huang, Q., Jacquelot, N., Preaudet, A., Hediyeh-zadeh, S., Souza-Fonseca-Guimarães, F., McKenzie, A. N. J., Hansbro, P. M., Davis, M. J., Mielke, L. A., Putoczki, T. L., et al. (2021) · Cancers · doi:10.3390/cancers13030559 · Cited by 53
“This is in sharp contrast to the recent findings reported by the Immunoscore® team whose findings strongly advocate for the quantification of CD3+ and CD8+ T cell infiltration in colorectal cancer [5,6] as prognostic markers to better define the risk of recurrence and survival, and to better guide clinicians in decisi…”
BackgroundMethodResultImmunosuppressive niche engineering at the onset of human colorectal cancer
Gatenbee, C., Baker, A., Schenck, R. O., Strobl, M. A. R., West, J., Neves, M. P., Hasan, S. Y., Lakatos, E., Martinez, P., Cross, W. C. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29027-8 · Cited by 58
“Moreover, non-metastatic CRC have an increased level of T-cell infiltration as compared to metastatic CRC (Pages et al., 2005).”
BackgroundImmunosurveillance in human non-viral cancers
Fridman, W. H., Mlecnik, B., Bindea, G., Pagès, F., & Galon, J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.011 · Cited by 57
Self-citationMogamulizumab and the Treatment of Ccr4-Positive T-Cell Lymphomas
Remer, M., Al‐Shamkhani, A., Glennie, M. J., & Johnson, P. (2014) · Immunotherapy · doi:10.2217/imt.14.94 · Cited by 59
Cooperativity of adaptive and innate immunity: implications for cancer therapy
Shanker, A., & Marincola, F. M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1053-z · Cited by 60
New Trends in Cancer Therapy: Targeting Ion Channels and Transporters
Arcangeli, A., & Becchetti, A. (2010) · Pharmaceuticals · doi:10.3390/ph3041202 · Cited by 59
“However, TEM cells exert protective effects only in some cancer types, but not others [123–125].”
BackgroundRauser, S., Langer, R., Tschernitz, S., Gais, P., Jütting, U., Feith, M., Höfler, H., & Walch, A. K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-608 · Cited by 57
“Studies on colorectal cancer showed that TILs predict survival better than conventional anatomical staging and that a high density of CD45RO+ lymphocytes is correlated with the absence of lymphatic vessel invasion [10,11].”
BackgroundEveno, C., Nemeth, J., Soliman, H. R., et al. (2010) · Archives of Surgery · doi:10.1001/archsurg.2009.224 · Cited by 53
Koganemaru, S., Inoshita, N., Miura, Y., Miyama, Y., Fukui, Y., Ozaki, Y., Tomizawa, K., Hanaoka, Y., Toda, S., Suyama, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13229 · Cited by 55
The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis.
Grandhi, R. K., Lee, S. J., & Abd-Elsayed, A. A. (2017) · PubMed Central · Cited by 67
Stoltzfus, C. R., Sivakumar, R., Kunz, L., Olin, B. E., Menietti, E., Speziale, D., Adelfio, R., Bacac, M., Colombetti, S., Perro, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726492 · Cited by 57
Sissy, C. E., Kirilovsky, A., Lagorce, C., Marliot, F., Custers, P. A., Dizdarevic, E., Sroussi, M., Castillo-Martín, M., Haicheur, N., Dermani, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00586 · Cited by 60
“9 10-12 To our knowledge, the IS test is the fi rst and only internationally validated 12 standardized assay 13 for quantifying the immune in fi ltrate.”
MethodSelf-citationImmune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Bograd, A. J., Suzuki, K., Vertes, E., Colovos, C., Morales, E. A., Sadelain, M., & Adusumilli, P. S. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1103-6 · Cited by 52
Complement anaphylatoxins as immune regulators in cancer
Sayegh, E. T., Bloch, O. G., & Parsa, A. T. (2014) · Cancer Medicine · doi:10.1002/cam4.241 · Cited by 55
Caie, P. D., Turnbull, A., Farrington, S. M., Oniscu, A., & Harrison, D. J. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-156 · Cited by 53
“Several studies incorporate image analysis, for example the quantification of immune infiltrate in the CRC microenvironment [32,33], and demonstrate the advantages this methodology could bring to the clinic.”
Kim, H., Kim, H., Cho, H. W., Kim, S. Y., Song, K., Hyung, W. J., Park, C., & Kim, C. G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22038 · Cited by 52
Ahn, J., Song, E., Oh, H., Song, D. E., Kim, W. G., Kim, T. Y., Kim, W. B., Shong, Y. K., & Jeon, M. J. (2019) · Thyroid · doi:10.1089/thy.2018.0684 · Cited by 53
Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Glaire, M. A., Domingo, E., Sveen, A., Bruun, J., Nesbakken, A., Nicholson, G., Novelli, M. R., Lawson, K., Oukrif, D., Kildal, W., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0540-4 · Cited by 64
Bioinformatics for cancer immunology and immunotherapy
Charoentong, P., Angelova, M., Efremova, M., Gallasch, R., Hackl, H., Galon, J., & Trajanoski, Z. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1354-x · Cited by 55
“For example, our previous results have shown the close correlation between the ‘‘high’’ intra-and peri-tumoral adaptive immune reaction in colorectal carcinoma and a good prognosis, and inversely, a ‘‘low’’ density of T cells was correlated with a poor prognosis [7, 8].”
ResultSelf-citationAkce, M., Farran, B., Switchenko, J. M., Rupji, M., Kang, S., Khalil, L. E., Ruggieri, A. N., Olson, B. M., Shaib, W. L., Wu, C. S.-Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007235 · Cited by 62
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer
Arens, R., van Hall, T., van der Burg, S. H., OSSENDORP, F. A., & Melief, C. J. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.008 · Cited by 58
“induction of effector-memory type T-cells [36,175] should further help to materialize the full potential of synthetic peptide vaccines combined with other immunotherapies and conventional thera-”
Background
Metadata
- Authors
- Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Galon, J.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Graz University of Technology (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-22
- Volume
- 353
- Issue
- 25
- Pages
- 2654-2666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096151993
- Semantic Scholar
- 608c79dfb95b1632f3cda7f427350880ee435e8a
- Cited by
- 2,135
- References
- 32
- Citations by year
- 2026: 27 · 2025: 57 · 2024: 66 · 2023: 118 · 2022: 117 · 2021: 141 · 2020: 130 · 2019: 123 · 2018: 123 · 2017: 136 · 2016: 135 · 2015: 145 · 2014: 115 · 2013: 135 · 2012: 108
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- colorectal cancer, effector memory T cells, tumor-infiltrating lymphocytes, CD8+ T cells, CD45RO+ memory T cells, T-cell markers, lymphatic invasion, perineural invasion, interferon-gamma, granzyme B, granulysin, IRF1, disease-free survival, overall survival, antitumor immunity
- MeSH terms
- Analysis of Variance, Embolism, Flow Cytometry, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger, T-Lymphocytes, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Survival Analysis, Polymerase Chain Reaction, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Microarray Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.